NHLBI integrated guidelines on cardiovascular disease risk reduction: Can we clarify the controversy about cholesterol screening and treatment in childhood?

Clinical Chemistry

Volumn 58, Issue 12, 2012, Pages 1626-1630

  De Ferranti, Sarah D ^a,b   Daniels, Stephen R ^c,d   Gillman, Matthew ^a   Vernacchio, Louis ^a,e   Plutzky, Jorge ^a,f   Baker, Annette L ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Children's Hospital Colorado   (United States)

^d CHILDREN S HOSPITAL COLORADO   (United States)

^e LLP   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

BEHAVIOR CHANGE; CANCER SCREENING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FOLLOW UP; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCREENING TEST;

CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK; UNITED STATES;

EID: 84870384374     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.182089     Document Type: Note

References (0)